NRx Pharmaceuticals NRXP: Prominently Featured in Psychiatrist.com; Article Titled "How NRx Could Upend the Fight Against Depression and Suicide"
Washingtoner/10268863

Trending...
NRXP NASDAQ NRXP 2 NRXP 3 NRXP 4 NRXP 5 Corporate Ads
Substantial Funding Agreements, Debt Resolution and Successful Clinical Trial Progress Towards Accelerated Drug Approval

RADNOR, Pa. - Washingtoner -- NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain

NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

NRx Pharmaceuticals, Inc. Featured on Psychiatrist.com: "How NRx Could Upend the Fight Against Depression and Suicide"

In a high recognition biopharma industry feature, NRXP has been profiled in an article published on Psychiatrist.com.  This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.

The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found at this direct link: https://www.psychiatrist.com/news/how-nrx-could-upend-the-fight-against-depression-and-suicide/.

More on Washingtoner
The author notes:

"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."

"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."

"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."

Nearly 4 million Americans planned suicide in 2022, with estimates suggesting that two-thirds of cases are associated with a mood disorder.

NRX-101 is an oral, fixed-dose combination of D-cycloserine and lurasidone being developed to treat treatment-resistant bipolar depression with suicidality or akathisia.

NRX-100 is an IV ketamine formulation being studied as a treatment for acute suicidal crises in all forms of depression, including bipolar depression.

The potential of these two NRXP therapies is monumental.  Bipolar disorder presents a significant global health challenge, mostly because of its close ties to higher suicide risk during depressive episodes.  Suicidal Depression affects millions of people every year; a pharmacologic treatment is a critical need.

The lack of FDA-approved pharmacological treatments targeting suicidal and bipolar depression with suicidality or akathisia in today's market underscores the need for more innovative therapies. And, if approved, these new NRXP treatments would be the first FDA-approved pharmaceutical regimens developed to treat these in patients struggling with suicidal behavior, ideation, or depression.

It's not an overstatement to say that NRXP could not only improve the quality of life for millions of people. It would also significantly cut the suicide rates among those affected.

More on Washingtoner
Participation at New York Global Investment Conference

NRXP has been featured at an important Global Investment Conference held in New York City on September 9-11, 2024.

Investors can listen to the full NRXP presentation via the following link www.hcwevents.com/annualconference

Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics

NRXP has also announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, NRXP has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. NRXP anticipates potential operations in the United States, France, and the United Kingdom.

This non-dilutive acquisition funding is in addition to the over $60 million in potential equity funding previously offered upon public listing of NRXP spin-off HOPE Therapeutics shares on a public exchange.

To Review $NRXP visit: https://www.nrxpharma.com/ or https://compasslivemedia.com/case-study/nrx-pharmaceuticals/

Media Contact

Company Name: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
Contact Person: Matthew Duffy, Chief Business Officer

Company Website: https://www.nrxpharma.com/
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Home Country: United States

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website

Contact
Corporate Ads
***@gmail.com


Source: Corporate Ads
Show All News | Report Violation

0 Comments

Latest on Washingtoner
_catLbl0 _catLbl1